Sam Fazeli

I stopped you there.

It's that first time that gave him the experience.

So we need to also acknowledge that some people can have their first time.

Anyway, so look, we're getting close to the hour.

I've got a couple more questions left.

2026, I'm looking at...

what sort of data sets or technologies, I don't want to call them hot areas.

I'm going to call out one and see whether you've got one that you want to add.

Bi-specifics.

Now, we've all had bi-specifics.

We know bi-specifics.

A lot of them have been in the world of CD3 T-cell engagers.

However, the real hardcore data for bi-specifics with the idea of I've got two mechanisms of action, not CD3,

on the same cell, so TIGIT PD1, CTLA4 PD1, VEGF PD1, I mean, they all happen to be that sort of world.

Of course, we've got the ribravant from J&J in terms of CMET and EGFR that's already approved and proven, but I'm going to pitch by specifics of that elk as the proof of whether the idea of biology of it, i.e.

the

the two mechanisms on the same cell at the same time becomes a reality next year or not.

So I'm rooting for it.

I'm hopeful for it.

Not any particular one, but I quite like still the AstraZeneca revlogostomic approach, which is TIGIT PD-1.